These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16309031)

  • 1. [Is depot formulation a long-term optimal treatment option?].
    Musch A
    Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031
    [No Abstract]   [Full Text] [Related]  

  • 2. Depot neuroleptic therapy: clinical considerations.
    Remington GJ; Adams ME
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Longterm therapy of schizophrenia].
    Pajonk FG; Wobrock T; Falkai P
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 10. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 11. Approaches to the problem of preventing hazards of long-term neuroleptic treatment and of avoiding unnecessary drugs.
    Kristjansen P
    Adv Biochem Psychopharmacol; 1980; 24():505-11. PubMed ID: 6105796
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term therapy with depot neuroleptics. Prevention of recurrence in chronic schizophrenic patients].
    Bergener M; Husser J; Kranzhoff EU; Charap A
    Fortschr Med; 1986 Oct; 104(40):756-60. PubMed ID: 2877927
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of schizophrenia. Long-term clinical studies with special reference to the combination of psychotherapy with depot neuroleptics.
    Lindberg D
    Acta Psychiatr Scand Suppl; 1981; 289():1-26. PubMed ID: 6110314
    [No Abstract]   [Full Text] [Related]  

  • 15. Depot antipsychotics in practice. Their rôle in schizophrenia and related psychoses.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-78. PubMed ID: 2881965
    [No Abstract]   [Full Text] [Related]  

  • 16. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
    Patel MX; De Zoysa N; Bernadt M; David A
    J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S; Müller P; Koller M
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 19. [Psychological aspects of depot treatment of schizophrenic syndromes].
    Jacobsson L; Odling H
    Lakartidningen; 1980 Oct; 77(40):3522-6. PubMed ID: 6109045
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological standards in schizophrenia treatment].
    Jarema M; Kiejna A; Landowski J; Meder J; Jolanta RJ; Rybakowski J
    Psychiatr Pol; 2006; 40(6):1171-205. PubMed ID: 17444297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.